The meaning of MULTIPLE MYELOMA is a disease of bone marrow that is characterized by the presence of numerous myelomas in various bones of the body.
Multiple Myeloma Immunotherapy By The ASCO Post Staff/July 2024 Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to ch...
*Preliminary results based on interim data, are subject to change. EasyM™ vs Comparable Methods. Explore our recent publications I’m a Clinician. Discover the advantages of EasyM™ mass spectrometry-based blood test for MRD monitoring in multiple myeloma...
BECK Owing to the fact that Bence-Jones proteinuria and multiple myeloma are conditions of rare occurrence, one not only should feel justified, but also should feel it a duty to the profession to report individual cases, especially so long as we need more light on the pathologic and clinical...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and renal failure. In approximately 30% of cases, MM is discovered through routine blood screening when patients are...
Proteasome inhibitorstrigger the death of myeloma cells by loading them up with defective proteins. Bortezomib (Velcade) is one that’s often used. It can be injected into a vein or under theskin. Other proteasome inhibitors include carfilzomib (Kyprolis), which you get in an IV, and ixazomib...
Khan, MBBS, assistant professor in the division of hematology at The Ohio State University Comprehensive Cancer Center – The James, discusses the recent updates to data on the use of idecabtagene vicleucel (ide-cel; Abecma) in patients w...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
S5C, D). These results suggested inter-myeloma heterogeneity could be explained by well-known oncogenic drivers and distinct transcriptional signatures. To further investigate intral-tumor heterogeneity (ITH), we performed clustering analysis on PCs for each MM individually and combined their CNA clones...